Short description
MaxiVAX is a Swiss clinical-stage biotechnology company.
Description
MaxiVAX is a Swiss clinical-stage biotechnology company, currently performing a first-in-man (phase I) trial in various tumours with MVX-ONCO-1.
MaxiVAX’ mission is to develop alternative solutions to “established cancer therapies” that are more effective, are personalized and enable the patient to fight his own disease. MaxiVAX’ first treatment, MVX-ONCO-1 has been classified as an Advanced Therapeutic Product by the European Medicines Agency. The resulting approval procedure is different than that of a traditional drug and should generally allow a faster development until market approval with fewer and less extensive clinical trials.
Last funding
Cannot Access
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Geneva, Geneve, Switzerland, Europe
Founded on
January 1, 2005
Non-profit?
No
Acquired?
No
Employees count
1-10
Revenue range
$34056 - 789030
Sign in for full access
Investors
Noaccessforu
Sign in for full access
Founders
Bernard Mach, Nicolas Mach